CannTrust Stock Price, News & Analysis (NYSE:CTST)

CannTrust trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTST."

CannTrust is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for CannTrust.

8 analysts have issued twelve-month price objectives for CannTrust's stock. Their predictions range from C$2.00 to C$7.00. On average, they anticipate CannTrust's share price to reach C$4.50 in the next twelve months. This suggests a possible upside of 240.9% from the stock's current price. View Analyst Price Targets for CannTrust.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CannTrust in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for CannTrust.

News headlines about CTST stock have been trending somewhat positive this week, InfoTrie reports. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. CannTrust earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for CannTrust.

CannTrust saw a increase in short interest in September. As of September 15th, there was short interest totalling 12,990,000 shares, an increase of 6.3% from the August 15th total of 12,220,000 shares. Based on an average daily volume of 4,290,000 shares, the short-interest ratio is currently 3.0 days. Currently, 14.7% of the shares of the company are sold short. View CannTrust's Current Options Chain.

Some companies that are related to CannTrust include Axsome Therapeutics (AXSM), CannTrust (CNTTF), Principia Biopharma (PRNB), Omeros (OMER), Stoke Therapeutics (STOK), Vanda Pharmaceuticals (VNDA), Rhythm Pharmaceuticals (RYTM), Wave Life Sciences (WVE), Organogenesis (ORGO), Emisphere Technologies (EMIS), Kura Oncology (KURA), Revance Therapeutics (RVNC), Karyopharm Therapeutics (KPTI), Cytokinetics (CYTK) and Rocket Pharmaceuticals (RCKT).

Based on aggregate information from My MarketBeat watchlists, some companies that other CannTrust investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Aphria (APHA), KushCo (KSHB), Aurora Cannabis (ACB), Cronos Group (CRON), OrganiGram (OGI), Nokia Oyj (NOK), HEXO (HEXO) and Aphria (APHA).

CannTrust's stock is owned by many different of retail and institutional investors. Top institutional investors include Legacy Advisors LLC (0.04%). Company insiders that own CannTrust stock include Aubrey Dan, Financial Corporation Forum, Mark Litwin and Mitchell J Sanders. View Institutional Ownership Trends for CannTrust.

CTST stock was sold by a variety of institutional investors in the last quarter, including Legacy Advisors LLC. View Insider Buying and Selling for CannTrust.

Shares of CTST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CTST stock can currently be purchased for approximately C$1.32.

CannTrust has a market capitalization of C$186.75 million and generates C$35.22 million in revenue each year. The company earns C$-10,460,000.00 in net income (profit) each year or C($0.11) on an earnings per share basis. CannTrust employs 576 workers across the globe.View Additional Information About CannTrust.

The official website for CannTrust is http://www.canntrust.ca/.

CannTrust's mailing address is 3280 LANGSTAFF ROAD UNIT 1, VAUGHAN A6, L4K 4Z8. The company can be reached via phone at 64-7872-2300 or via email at [email protected]